Evidence map›Paper›PMID 40575322›Full record

ArticleJACS Au2025

Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation.

Katherine A Gosselé, Irene Latino, Eleen Laul, Mariia S Kirillova, Vlad Pascanu, Emanuele Carloni, Rajiv K Bedi, Chiara Pizzichetti, Amedeo Caflisch, Santiago F González and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katherine A GosseléDepartment of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.ORCID https://orcid.org/0009-0009-9719-2013
Irene LatinoFaculty of Biomedical Sciences, Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona CH-6500, Switzerland.
Eleen LaulDepartment of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.
Mariia S KirillovaDepartment of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.
Vlad PascanuDepartment of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.
Emanuele CarloniFaculty of Biomedical Sciences, Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona CH-6500, Switzerland.
Rajiv K BediDepartment of Biochemistry, University of Zurich, Zurich CH-8057, Switzerland.ORCID https://orcid.org/0000-0002-8193-9006
Chiara PizzichettiFaculty of Biomedical Sciences, Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona CH-6500, Switzerland.
Amedeo CaflischDepartment of Biochemistry, University of Zurich, Zurich CH-8057, Switzerland.ORCID https://orcid.org/0000-0002-2317-6792
Santiago F GonzálezFaculty of Biomedical Sciences, Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona CH-6500, Switzerland.
Cristina NevadoDepartment of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.ORCID https://orcid.org/0000-0002-3297-581X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor α (TNF-α) is a central driver of inflammation in autoimmune conditions such as Crohn's disease and rheumatoid arthritis (RA). Targeting epigenetic regulators involved in cytokine expression holds therapeutic promise, yet the precise role of the CBP/EP300 bromodomains (BRDs) in modulating immune responses remains poorly understood. Here, we introduce a distinct class of selective CBP/EP300-BRD inhibitors based on a unique 3-methylcinnoline acetyl-lysine mimic, identified through high-throughput fragment docking. These inhibitors significantly reduce TNF-α-driven cytokine expression

Indexed as

bromodomain inhibitorsCBP/EP300epigeneticsinflammationNFκBTNF-α

Identifiers

PMID40575322
PMCPMC12188386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.